About Us
COG Research Foundation, LLC is a California 501(c)(3) entity that was founded in 2024 and designed to become the federal grantee organization for the Children's Oncology Group (COG). The COG, a member of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN), is the world’s largest organization devoted exclusively to childhood and adolescent cancer research.
|
COG unites over 12,000 experts in childhood cancer at more than 220 leading children’s hospitals, universities, and cancer centers across the United States, Canada, Australia, New Zealand, and Saudi Arabia in the fight against childhood cancer.
Today, more than 80% of the 16,000 children and adolescents diagnosed with cancer each year in the United States are cared for at COG member institutions. Research performed by COG institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. |
|
COG conducts more than 100 active clinical trials, with approximately 12,000 patients registered on COG trials each year. These trials include front-line treatment for many types of childhood cancers, studies aimed at determining the underlying biology of these diseases, and trials involving new and emerging treatments, supportive care, and survivorship.
Since COG's founding, it has endeavored to improve the outcome for every successive generation of children with cancer.
COG recognizes that the increasing pace of scientific discovery will demand ongoing and farther-reaching collaborations, greater diversity in our multidisciplinary teams of disease and translational science experts to innovate new methods and prioritize clinical research goals, and unprecedented participation of the childhood cancer clinical research community to take full advantage of the current era of discovery.
Since COG's founding, it has endeavored to improve the outcome for every successive generation of children with cancer.
COG recognizes that the increasing pace of scientific discovery will demand ongoing and farther-reaching collaborations, greater diversity in our multidisciplinary teams of disease and translational science experts to innovate new methods and prioritize clinical research goals, and unprecedented participation of the childhood cancer clinical research community to take full advantage of the current era of discovery.
